comparemela.com

Latest Breaking News On - Chronic lymphocytic leukemia treatment - Page 5 : comparemela.com

BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib)

BRUKINSA demonstrated superior objective response rate by investigator assessment in the planned interim analysisBRUKINSA was associated with a statistically significant lower risk of atrial fibrillation or flutter Company to host investor call and webcast on Friday, June 11 at noon ETCAMBRIDGE, Mass. & BEIJING (BU.

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Calquence approved in Japan for CLL

  relapsed or refractory chronic lymphocytic leukaemia   progression after 12 months vs. 68% for comparators   AstraZeneca s Calquence (acalabrutinib), a next-generation, selective Bruton s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]).   The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ASCEND Phase III trial and a Phase I trial in Japanese patients, showing Calquence monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus a standard treatment of rituximab, a monoclonal antibody, combined with the physician s choice of idelalisib, a PI3-kinase inhibitor or bendamustine, a chemotherapy.

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Calquence met primary endpoint against ibrutinib

  against ibrutinib in chronic lymphocytic leukaemia   Superior safety on key secondary endpoint of atrial fibrillation Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca s Calquence (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukaemia (CLL) compared to ibrutinib.   The trial also met a key secondary endpoint for safety, showing patients treated with Calquence had statistically significantly lower incidence of atrial fibrillation compared to patients treated with ibrutinib. Atrial fibrillation is an irregular heart rate that can increase the risk of stroke, heart failure and other heart-related complications . 1 Further hierarchical testing revealed no difference for Grade 3 or higher infections or Richter s transformation. There was a descriptive trend for numerically fa

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.